Cite
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
MLA
Hanfstein, Benjamin, et al. “Distinct Characteristics of E13a2 versus E14a2 BCR-ABL1 Driven Chronic Myeloid Leukemia under First-Line Therapy with Imatinib.” Haematologica, vol. 99, no. 9, Sept. 2014, pp. 1441–47. EBSCOhost, https://doi.org/10.3324/haematol.2013.096537.
APA
Hanfstein, B., Lauseker, M., Hehlmann, R., Saussele, S., Erben, P., Dietz, C., Fabarius, A., Proetel, U., Schnittger, S., Haferlach, C., Krause, S. W., Schubert, J., Einsele, H., Hänel, M., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., … Müller, M. C. (2014). Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica, 99(9), 1441–1447. https://doi.org/10.3324/haematol.2013.096537
Chicago
Hanfstein, Benjamin, Michael Lauseker, Rüdiger Hehlmann, Susanne Saussele, Philipp Erben, Christian Dietz, Alice Fabarius, et al. 2014. “Distinct Characteristics of E13a2 versus E14a2 BCR-ABL1 Driven Chronic Myeloid Leukemia under First-Line Therapy with Imatinib.” Haematologica 99 (9): 1441–47. doi:10.3324/haematol.2013.096537.